2024-03-29T15:15:34Z
https://tsukuba.repo.nii.ac.jp/oai
oai:tsukuba.repo.nii.ac.jp:02001688
2022-04-27T09:52:30Z
2780:2206
3:62:5588:1635225066520
KEYNOTE-676: Phase III study of BCG and pembrolizumab for persistent/recurrent high-risk NMIBC
Kamat, Ashish M
Shore, Neal
Hahn, Noah
Alanee, Shaheen
西山, 博之
ニシヤマ, ヒロユキ
NISHIYAMA, Hiroyuki
Shariat, Shahrokh
Nam, Kijoeng
Kapadia, Ekta
Frenkl, Tara
Steinberg, Gary
Background: Nonmuscle-invasive bladder cancer (NMIBC) is the most common form of bladder cancer, with high rates of disease recurrence and progression. Current treatment for high-risk NMIBC involves Bacillus Calmette-Guérin (BCG) therapy, but treatment options are limited for patients with recurrent or BCG-unresponsive disease. Aberrant programmed death 1 signaling has been implicated in BCG resistance and bladder cancer recurrence and progression, and pembrolizumab has shown efficacy in patients with BCG-unresponsive high-risk NMIBC. Aim: To describe the rationale and design for the randomized, comparator-controlled Phase III KEYNOTE-676 study, which will evaluate the efficacy and safety of pembrolizumab in combination with BCG in patients with persistent/recurrent high-risk NMIBC after BCG induction therapy.
journal article
Future Medicine
2020-04
application/pdf
Future Oncology
10
16
507
516
1479-6694
AA1206226X
https://tsukuba.repo.nii.ac.jp/record/2001688/files/FO_16-10.pdf
eng
32162533
https://doi.org/10.2217/fon-2019-0817
This work is licensed under the Attribution-NonCommercial-NoDerivatives 4.0 Unported License. To view a copy of this license, visit http://creativecommons.org/licenses/by-nc-nd/4.0/
open access